Sun Pharmaceutical Industries Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Dilip Shanghvi
Chief executive officer
₹64.8m
Total compensation
| CEO salary percentage | 75.62% |
| CEO tenure | 32.4yrs |
| CEO ownership | 9.6% |
| Management average tenure | 1.3yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Earnings Miss: Sun Pharmaceutical Industries Limited Missed EPS By 22% And Analysts Are Revising Their Forecasts
Aug 04
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Will Pay A Dividend Of ₹5.50
Jun 27What Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Not Telling You
Jun 26Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Due To Pay A Dividend Of ₹5.50
May 25Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Well Worth Watching
May 15Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Shares May Have Run Too Fast Too Soon
Feb 23Analysts Are Updating Their Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Estimates After Its Third-Quarter Results
Feb 05Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 04Here's Why Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has Caught The Eye Of Investors
Jan 29Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18
Robust Product Pipeline And Market Expansion Drive Growth Amidst Challenges
U.S. and India sales, driven by market leadership and product launches, enhance revenue growth and net margins via economies of scale.Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | ₹104b |
| Mar 31 2025 | ₹65m | ₹49m | ₹109b |
| Dec 31 2024 | n/a | n/a | ₹114b |
| Sep 30 2024 | n/a | n/a | ₹111b |
| Jun 30 2024 | n/a | n/a | ₹104b |
| Mar 31 2024 | ₹61m | ₹46m | ₹96b |
| Dec 31 2023 | n/a | n/a | ₹89b |
| Sep 30 2023 | n/a | n/a | ₹85b |
| Jun 30 2023 | n/a | n/a | ₹84b |
| Mar 31 2023 | ₹55m | ₹41m | ₹85b |
| Dec 31 2022 | n/a | n/a | ₹42b |
| Sep 30 2022 | n/a | n/a | ₹41b |
| Jun 30 2022 | n/a | n/a | ₹39b |
| Mar 31 2022 | ₹51m | ₹38m | ₹33b |
| Dec 31 2021 | n/a | n/a | ₹64b |
| Sep 30 2021 | n/a | n/a | ₹62b |
| Jun 30 2021 | n/a | n/a | ₹60b |
| Mar 31 2021 | ₹46m | ₹35m | ₹29b |
| Dec 31 2020 | n/a | n/a | ₹24b |
| Sep 30 2020 | n/a | n/a | ₹15b |
| Jun 30 2020 | n/a | n/a | ₹7b |
| Mar 31 2020 | ₹43m | ₹32m | ₹38b |
| Dec 31 2019 | n/a | n/a | ₹40b |
| Sep 30 2019 | n/a | n/a | ₹43b |
| Jun 30 2019 | n/a | n/a | ₹30b |
| Mar 31 2019 | ₹263k | ₹1 | ₹27b |
Compensation vs Market: Dilip's total compensation ($USD739.95K) is below average for companies of similar size in the Indian market ($USD1.10M).
Compensation vs Earnings: Dilip's compensation has been consistent with company performance over the past year.
CEO
Dilip Shanghvi (70 yo)
Mr. Dilip Shantilal Shanghvi serves as MD at Sun Petrochemicals Private Limited. He serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Chairman of the Board | no data | ₹64.80m | 9.6% ₹ 381.7b | |
| COO, Head of Global Generics R&D | less than a year | ₹75.80m | 0.12% ₹ 4.8b | |
| Executive VP & CFO | less than a year | no data | no data | |
| EVP & Chief Information Officer | 1.3yrs | no data | no data | |
| VP, Head of Investor Relations & Strategic Projects | no data | no data | no data | |
| Company Secretary & Compliance Officer | 3.6yrs | no data | no data | |
| Director of Corporate Development | no data | ₹65.30m | no data | |
| Chief Human Resources Officer | 1.7yrs | no data | no data | |
| Head of India Business | no data | no data | 0.00042% ₹ 16.7m | |
| Head of Corporate Relations & CSR - India Regulatory Affairs | no data | no data | no data | |
| Executive Vice-President of Global Operations | no data | no data | no data | |
| Business Head of Western Europe | no data | no data | no data |
Experienced Management: SUNPHARMA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Chairman of the Board | 32.4yrs | ₹64.80m | 9.6% ₹ 381.7b | |
| COO, Head of Global Generics R&D | 2.2yrs | ₹75.80m | 0.12% ₹ 4.8b | |
| Whole-time Director | less than a year | no data | 0.12% ₹ 4.7b | |
| Non-Executive & Independent Director | 4.3yrs | ₹6.80m | no data | |
| Non-Executive Independent Director | 7.3yrs | ₹9.80m | 0.00033% ₹ 13.1m | |
| Independent Director | 2.2yrs | ₹6.60m | no data | |
| Lead Independent Director | 4.3yrs | ₹10.80m | no data |
Experienced Board: SUNPHARMA's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/25 17:58 |
| End of Day Share Price | 2025/08/25 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sun Pharmaceutical Industries Limited is covered by 81 analysts. 37 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashwin Mehta | Ambit Capital |
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |